Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.

@article{Mantovani2000TreatmentOA,
  title={Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin.},
  author={Luisa Mantovani and Giuseppe Lentini and Bettina Hentschel and Premaratne Dias Wickramanayake and Markus L{\"o}ffler and Volker Diehl and Hans Tesch},
  journal={British journal of haematology},
  year={2000},
  volume={109 2},
  pages={367-75}
}
Treatment with recombinant human erythropoietin (rhEPO) improves anaemia in approximately 20% of the patients with myelodysplastic syndromes (MDS). Recent reports suggest that a combination treatment with rhEPO plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) given for up to 18 weeks may result in a higher erythroid response rate than with rhEPO alone. We investigated the potential advantage of an even more prolonged schedule of combined rhG-CSF and rhEPO treatment to… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 32 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 56 references

Similar Papers

Loading similar papers…